Yang Zhang(张阳)

Show Academic Trajectory

Ego Network

D-Core

Research Interests

Author Statistics

Experience

Education

Bio

None

Papers30 papers

Sort

By YearBy Citation

A phase I, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced solid tumors or relapsed/refractory non-Hodgkin lymphoma

Li Zhang,Hongyun Zhao,Yuxiang Ma,Xin Zheng,Ji Jiang,Yang Zhang,Shaodong Hong, Guizhong Liu, Xiaohong She, Qingjiang Ni, Lvyu Zhu, Yi Zhu

Journal of Clinical Oncology, (2020): 3105-3105

Bibtex

Phase I study results of APG-115, a MDM2-p53 antagonist in Chinese patients with advanced liposarcoma and other solid tumors

Xing Zhang,Xizhi Wen, Guojuan Chen,Shan Zeng, Lichuang Men, Hengbang Wang, Shulan He,Yuxiang Ma,QiuZhong Pan,Yang Zhang,Ruiqing Peng,Desheng Weng

Journal of Clinical Oncology, (2020): 11542-11542

Bibtex

A phase I, dose-escalation and expansion study of TQ-B3139, a novel ALK TKI, in Chinese ALK or ROS1 positive advanced non-small cell lung cancer (NSCLC)

Yuxiang Ma,Nong Yang,Su Li,Hongyun Zhao,Liu Li, Haiyan Yang,Wenfeng Fang,Yang Zhang,Shaodong Hong,Yi Xiong, Chunhua Zhou, Yongchang Zhang

Journal of Clinical Oncology, (2020): 9585-9585

Bibtex

The preliminary efficacy and safety data of KN046 in patients failed on prior immune checkpoint inhibitors therapy

Hongyun Zhao,Yuxiang Ma,Yang Zhang,Shaodong Hong,Yunpeng Yang,Wenfeng Fang, June Xu, Hardy Van, Paul Kong, Fei Yang, Jingying Li, Yao Lu

Journal of Clinical Oncology, (2020): 3020-3020

Bibtex

A phase Ib study of a novel c-MET, AXL and VEGFR-2 inhibitor ningetinib and gefitinib combination therapy in Chinese EGFR-TKI resistant NSCLC with T790M negative

Hongyun Zhao, Lianke Liu,Yuxiang Ma,Jian Fang,Wenfeng Fang, Haiqing Ma,Yang Zhang, Guosheng Feng,Shaodong Hong,Shan Zeng, Bo Xie,Jun Ren

Journal of Clinical Oncology, (2020): 9583-9583

Bibtex

Abstract 579: Ensartinib (X-396), a novel ALK TKI, in Chinese ALK-positive non-small cell lung cancer: A phase I, dose-escalation and expansion study

Hongyun Zhao,Yuxiang Ma,Yang Zhang,Shaodong Hong,Wenfeng Fang,Yunpeng Yang,Jianjin Huang,Jing Zhao,Yan Huang,Lieming Ding,Li Mao, Giovanni Selvaggi

Cancer Research, (2020): 579-579

Bibtex

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer

Zhonghan Zhang,Yang Zhang, Fan Luo,Yuxiang Ma,Wenfeng Fang, Jing Zhan,Su Li,Yunpeng Yang,Yuanyuan Zhao,Shaodong Hong,Ting Zhou,Yaxiong Zhang

Clinical and translational medicine, (2020)

WOSBibtex

A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors

Xiao-Li Wei,Chao Ren,Feng-Hua Wang,Yang Zhang,Hong-Yun Zhao, Ben-Yan Zou,Zhi-Qiang Wang,Miao-Zhen Qiu,Dong-Sheng Zhang,Hui-Yan Luo,Feng Wang, Sheng Yao

Cancer communications (London, England), (2020)

WOSBibtex

First-in-human dose-escalation study of anti-EGFR ADC MRG003 in patients with relapsed/refractory solid tumors

Rui-hua Xu,Miao-Zhen Qiu,Yang Zhang,Xiao-Li Wei, Chaohong Hu

Journal of Clinical Oncology, (2020): 3550-3550

Bibtex

Phase Ia dose escalation of IBI318, a first-in-class bispecific anti-PD-1/PD-L1, in patients with advanced tumors

Rui-hua Xu,Hongyun Zhao,Xiao-Li Wei,Yang Zhang,Feng Wang,Zhiqiang Wang,Fenghua Wang,Yu-Hong Li, Ben-Yan Zou, Xiaomin Zhu, Wencheng Yu, Hui Zhou

Journal of Clinical Oncology, (2020): 3062-3062

Bibtex

KEYNOTE-032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non-Small-Cell Lung Cancer

Yuxiang Ma,Wenfeng Fang,Yang Zhang,Yunpeng Yang,Shaodong Hong,Yuanyuan Zhao, Shuang Xie, Jun Ge, HaoJin Zhou,Hongyun Zhao,Li Zhang

The oncologist, (2020)

WOSBibtex

A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas

Xing Zhang, Xizhi Wen, Chen Yang, Shan Zeng, Lichuang Men, Hengbang Wang,Yuxiang Ma,Yang Zhang, Ruiqing Peng, Desheng Weng, Li Zhang, Jiao Ji

Journal of Clinical Oncology, (2019): 3124-3124

Bibtex

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)

Zhonghan Zhang, Fan Luo,Yang Zhang,Yuxiang Ma,Shaodong Hong,Yunpeng Yang,Wenfeng Fang,Yan Huang,Li Zhang,Hongyun Zhao

Cancer communications (London, England), no. 1 (2019): 69

WOSBibtex

Modification of the tumor response threshold in patients of advanced non-small cell lung cancer treated with chemotherapy plus targeted agents: a pooled study from five clinical trials in one institution

Fan Luo, Zhonghan Zhang, Kunlun Liao,Yang Zhang,Yuxiang Ma,Zhihuang Hu, Kangmei Zeng,Yan Huang, Li Zhang,Hongyun Zhao

ANNALS OF TRANSLATIONAL MEDICINE, no. 12.0 (2019)

WOSBibtex

Ensartinib (X-396), a second-generation ALK TKI, in Chinese ALK-positive non-small cell lung cancer: A phase I, dose-escalation study

Wenfeng Fang,Yuxiang Ma,Jianjin Huang,Yang Zhang, Benyan Zou,Hongyun Zhao,Yunpeng Yang,Yan Huang, Jing Zhao,Lieming Ding,Fenlai Tan, Li Zhang

Journal of Clinical Oncology, (2018)

Bibtex

A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC)

Hongyun Zhao, Zhonghan Zhang, Fan Luo,Yuxiang Ma,Wenfeng Fang,Yunpeng Yang,Yang Zhang,Yan Huang, Li Zhang

Journal of Clinical Oncology, (2018)

Bibtex

RealPoint3D: Point Cloud Generation from a Single Image with Complex Background

Yan Xia,Yang Zhang,Dingfu Zhou,Xinyu Huang,Cheng Wang,Ruigang Yang

arXiv: Computer Vision and Pattern Recognition, (2018)

Cited by1EIBibtex

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

Wenfeng Fang,Yunpeng Yang,Yuxiang Ma,Shaodong Hong, Lizhu Lin, Xiaohui He,Jianping Xiong, Ping Li,Hongyun Zhao,Yan Huang,Yang Zhang,Likun Chen

The Lancet. Oncology, (2018)

Cited by5WOSBibtex

First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance

Yuxiang Ma,Xin Zheng,Hongyun Zhao,Wenfeng Fang,Yang Zhang, Jieying Ge, Lu Wang, Weicong Wang,Ji Jiang,Shaokun Chuai, Zhou Zhang,Wanhong Xu

Journal of Thoracic Oncology, no. 7 (2018): 968-977

Cited by7WOSBibtex

A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors

Rui-hua Xu, Li Y, Jiao Ji,Miaozhen Qiu,Yang Zhang, Wenqin Liu, Xiaohong Tian,Su Li, Hengbang Wang,Fenghua Wang, Dongsheng Zhang, Feng Wang

Journal of Clinical Oncology, (2018): 2593-2593

Cited by1Bibtex

View All

Base Info Papers Patents Projects